Dengue Fever Treatment Market Growth 2023 to 2033 | By Perrigo, ABIVAX, Mylan N.V, Pfizer, Sanofi

The global Dengue Fever Treatment Market size is expected to be worth US$ 877.82 million in 2023 and US$ 5435.25 million by 2033, with a CAGR of 20% from 2023 to 2033. Dengue Fever Therapy market expanded at an 11% CAGR between 2018 and 2022.

Dengue fever has increased rapidly in recent decades, according to the World Health Organisation. Because the majority of reported cases are asymptomatic, mild, or self-managed, the actual number of infections is greatly under-reported. According to studies, 3,766,153 cases and 3582 deaths have been reported as of December 19, 2022. Brazil (2,182,229), Vietnam (325 604), the Philippines (201,509), India (110,473), and Indonesia (94,355) have reported the majority of cases.

Get Full PDF Sample Copy of Latest Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16441

Market players are actively exploiting strategic collaborations with big pharmaceutical corporations or research institutes, mergers and acquisitions, and capacity expansion initiatives to provide better treatment of dengue fever. Several startups are launching clinical trials to provide significant dengue treatment. Singaporean business StratifiCare, for example, offers a severe dengue prediction kit. It employs a collection of proprietary biomarkers and a standardised laboratory assay platform. The solution is currently undergoing clinical testing. The kit can provide accuracy with 90% sensitivity and 97% specificity, lowering hospitalisation costs.

Key Takeaways from the Market Study

• The Dengue Fever Treatment market increased at an 11% CAGR between 2018 and 2022.
• From 2023 to 2033, the global Dengue Fever Treatment market is predicted to rise at a 20% CAGR.
• Dengue Fever Treatment Market is anticipated to reach US$ 5435.25 Million by 2033.
• Hospitals have the biggest market share, according to the FMI research.
• North America is anticipated to account for 25% of the Dengue Fever Treatment market.
• With a CAGR of 5% during the forecast period, the Asia Pacific market is expected to grow significantly throughout the forecast period. 

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering dengue fever treatments. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as presence of reputed regional pharmaceutical giants.” says an FMI analyst

For any queries linked with the report, ask an analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16441

Market Competition

Key players in the Dengue Fever Treatment market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi and Takeda Pharmaceutical Company Limited among other global players.

• Takeda Pharmaceutical Company Limited stated in March 2021 that the European Medicines Agency (EMA) had approved their TAK-003 dengue vaccine candidate, which is presently under investigation for preventing epidemics in people aged 4 to 60. Through 2021, the company plans to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand.

More Insights Available

Asia Pacific is the largest dengue treatment market, owing to the high incidence of dengue fever in the region, particularly in countries such as India, Indonesia, and Thailand. The increasing healthcare expenditure and the growing awareness of the disease in the region are also expected to drive market growth.

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16441

Key Segments Profiled in the Dengue Fever Treatment Industry Survey

Type:

• Drug
• Vaccines

Route of Administration:

• Oral
• Parenteral

End-User:

• Hospital
• Homecare
• Specialty Clinics
• Others

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs